BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wolf HK, Stöber C, Hohenfellner R, Leissner J. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas. Tumour Biol. 2001;22:328-336. [PMID: 11553864 DOI: 10.1159/000050635] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Mitra AP. Molecular substratification of bladder cancer: moving towards individualized patient management. Ther Adv Urol 2016;8:215-33. [PMID: 27247631 DOI: 10.1177/1756287216638981] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
2 Zhang G, Chen F, Cao Y, See WA. Bacillus Calmette-Guérin induces p21 expression in human transitional carcinoma cell lines via an immediate early, p53 independent pathway. Urologic Oncology: Seminars and Original Investigations 2007;25:221-7. [DOI: 10.1016/j.urolonc.2006.07.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
3 Queipo Zaragozá J, Ruiz Cerdá J, Palmero Martí L, Rubio Martínez L, Vera Sempere F, Jiménez Cruz J. Valor pronóstico de progresión de las moléculas reguladoras del ciclo celular en tumores vesicales T1G3. Actas Urológicas Españolas 2005;29:261-8. [DOI: 10.1016/s0210-4806(05)73237-x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
4 Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Requena MJ, Montironi R. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 2004;122:444-52. [PMID: 15362377 DOI: 10.1309/LTFU-3UUM-BY09-5HUM] [Cited by in Crossref: 4] [Cited by in F6Publishing: 21] [Article Influence: 0.2] [Reference Citation Analysis]
5 Park J, Song C, Shin E, Hong JH, Kim C, Ahn H. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urologic Oncology: Seminars and Original Investigations 2013;31:849-56. [DOI: 10.1016/j.urolonc.2011.06.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
6 Gallucci M, Vico E, Merola R, Leonardo C, Sperduti I, Felici A, Sentinelli S, Cantiani R, Orlandi G, Cianciulli A. Adverse genetic prognostic profiles define a poor outcome for cystectomy in bladder cancer. Experimental and Molecular Pathology 2007;83:385-91. [DOI: 10.1016/j.yexmp.2007.08.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
7 Krüger S, Thorns C, Stöcker W, Müller-kunert E, Böhle A, Feller AC. Prognostic Value of MCM2 Immunoreactivity in Stage T1 Transitional Cell Carcinoma of the Bladder. European Urology 2003;43:138-45. [DOI: 10.1016/s0302-2838(02)00580-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
8 Visapää H, Seligson D, Eeva M, Gaber F, Rao J, Belldegrun A, Palotie A. 8q24 amplification in transitional cell carcinoma of bladder. Appl Immunohistochem Mol Morphol 2003;11:33-6. [PMID: 12610354 DOI: 10.1097/00129039-200303000-00006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
9 Peiró G, Mayr D, Hillemanns P, Löhrs U, Diebold J. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol. 2004;17:227-287. [PMID: 14752523 DOI: 10.1038/modpathol.3800006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
10 Mitra AP, Daneshmand S. Molecular Prognostication in Bladder Cancer. In: Daneshmand S, Chan KG, editors. Genitourinary Cancers. Cham: Springer International Publishing; 2018. pp. 165-91. [DOI: 10.1007/978-3-319-93339-9_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Bartsch G, Mitra AP, Cote RJ. Expression profiling for bladder cancer: strategies to uncover prognostic factors. Expert Rev Anticancer Ther 2010;10:1945-54. [PMID: 21110760 DOI: 10.1586/era.10.131] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
12 Saint F, Le Frere Belda M, Quintela R, Hoznek A, Patard J, Bellot J, Popov Z, Zafrani ES, Abbou CC, Chopin DK, Gil Diez de Medina S. Pretreatment p53 Nuclear Overexpression as a Prognostic Marker in Superficial Bladder Cancer Treated with Bacillus Calmette–Guérin (BCG). European Urology 2004;45:475-82. [DOI: 10.1016/j.eururo.2003.11.018] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
13 Hänze J, Kessel F, Di Fazio P, Hofmann R, Hegele A. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells. Biomed Pharmacother 2018;106:316-25. [PMID: 29966976 DOI: 10.1016/j.biopha.2018.06.110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
14 Lopez-beltran A, Luque R, Alvarez-kindelan J, Quintero A, Merlo F, Carrasco J, Requena M, Montironi R. Prognostic Factors in Stage T1 Grade 3 Bladder Cancer Survival: The Role of G1–S Modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and Proliferation Index (ki67-MIB1). European Urology 2004;45:606-12. [DOI: 10.1016/j.eururo.2003.11.011] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 4.5] [Reference Citation Analysis]
15 Mitra AP, Bartsch CC, Cote RJ. Strategies for molecular expression profiling in bladder cancer. Cancer Metastasis Rev 2009;28:317-26. [PMID: 19997771 DOI: 10.1007/s10555-009-9196-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
16 Esuvaranathan K, Chiong E, Thamboo TP, Chan YH, Kamaraj R, Mahendran R, Teh M. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 2007;109:1097-105. [PMID: 17311305 DOI: 10.1002/cncr.22503] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
17 Ozden SA, Ozyurt H, Ozgen Z, Kilinc O, Oncel M, Gul AE, Karadayi N, Serakinci N, Kan B, Orun O. Prognostic role of sensitive-to-apoptosis gene expression in rectal cancer. World J Gastroenterol 2011; 17(44): 4905-4910 [PMID: 22171132 DOI: 10.3748/wjg.v17.i44.4905] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
18 Luo Y, Zhang X, Mo M, Tan Z, Huang L, Zhou H, Wang C, Wei F, Qiu X, He R, Chen G. High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved. Medicine (Baltimore) 2016;95:e3337. [PMID: 27082587 DOI: 10.1097/MD.0000000000003337] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
19 Shaker OG, Hammam OA, El Leithy TR, El Ganzoury H, Wishahi MM, Mikhailidis DP. Molecular markers and bladder carcinoma: Schistosomal and non-schistosomal. Clin Biochem 2011;44:237-44. [PMID: 20934419 DOI: 10.1016/j.clinbiochem.2010.09.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
20 Lorenzo Gómez MF, Schroeder G. [The role of tumor markers in prognosing transitional bladder cancer]. Actas Urol Esp 2003;27:501-12. [PMID: 12938579 DOI: 10.1016/s0210-4806(03)72963-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Sekula P, Pressler JB, Sauerbrei W, Goebell PJ, Schmitz-Dräger BJ. Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example. BMJ Open 2016;6:e009972. [PMID: 27531721 DOI: 10.1136/bmjopen-2015-009972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
22 Piaton E, Faÿnel J, Ruffion A, Lopez JG, Perrin P, Devonec M. p53 immunodetection of liquid-based processed urinary samples helps to identify bladder tumours with a higher risk of progression. Br J Cancer 2005;93:242-7. [PMID: 15999101 DOI: 10.1038/sj.bjc.6602684] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
23 Mitra AP, Bartsch G, Cote RJ. Risk Factors and Molecular Features Associated with Bladder Cancer Development. In: Hansel DE, Lerner SP, editors. Precision Molecular Pathology of Bladder Cancer. Cham: Springer International Publishing; 2018. pp. 3-28. [DOI: 10.1007/978-3-319-64769-2_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]